Comentis

First (human) data on a new BACE inhibitor !! South San Francisco, CA – January 7, 2008 – CoMentis, Inc., a privately held biopharmaceutical company, announced today that it has completed a Phase I study of its proprietary, orally bioavailable, small-molecule beta-secretase inhibitor, CTS-21166, which is being developed as a disease-modifying treatment for Alzheimer’s disease. Results from the study indicate that CTS-21166 is safe and well-tolerated. Pharmacodynamic proof of activity was achieved as subjects displayed a robust, sustained and dose-related reduction in plasma amyloid beta in both area-under-curve (AUC) reduction and peak reduction with effects lasting over 72 hours. Single dose administration of CTS-21166 produced a greater than 60% reduction of plasma amyloid beta measured either by AUC over 24 hours or as a maximal reduction relative to predose levels. The top doses of CTS-21166 further demonstrated a sustained reduction in AUC that was greater than 40% over 72 hours.